. 2018 Jul 24;32(5):425–440. doi: 10.1007/s40259-018-0295-0

Table 3.

Monoclonal antibodies for subcutaneous administration in oncology [64, 65]

Molecule	Brand name (originator)	Dosing frequency	Injection volume	Device
Anti-HER2 mAb
Trastuzumab	Herceptin (Roche)^a,b	q3w	5 ml	Vial and syringe
Anti-CD20 mAb
Rituximab	MabThera/Rituxan Hycela (Roche)^a,b	q3w–q3m^c	11.7–13.4 ml	Vial and syringe

CD cluster of differentiation, HER human epidermal growth factor receptor, mAb monoclonal antibody, qXw once every X weeks, qXm once every X months

^aSubcutaneous and intravenous formulation marketed

^bSubcutaneous formulation contains recombinant human hyaluronidase (rHuPH20)

^cDepending on the type of follicular lymphoma